ImmunoCellular Therapeutics - Delisted Pink Sheet
ImmunoCellular Therapeutics is currently unavailable and cannot be used in your analysis. The information on this page reflects the last day ImmunoCellular Therapeutics was actively traded.
Valuation
Check how we calculate scores
ImmunoCellular Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. ImmunoCellular Therapeutics market risk premium is the additional return an investor will receive from holding ImmunoCellular Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ImmunoCellular Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although ImmunoCellular Therapeutics' alpha and beta are two of the key measurements used to evaluate ImmunoCellular Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (1.38) | |||
| Treynor Ratio | (0.21) |
ImmunoCellular Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmunoCellular Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of ImmunoCellular Therapeutics could also be used in its relative valuation, which is a method of valuing ImmunoCellular Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
ImmunoCellular Therapeutics Corporate Directors
ImmunoCellular Therapeutics corporate directors refer to members of an ImmunoCellular Therapeutics board of directors. The board of directors generally takes responsibility for the ImmunoCellular Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of ImmunoCellular Therapeutics' board members must vote for the resolution. The ImmunoCellular Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Gregg Lapointe | Independent Director | Profile | |
| Rahul Singhvi | Lead Independent Director | Profile | |
| Mark Schlossberg | Independent Director | Profile | |
| Anthony Lapointe | Independent Director | Profile |
Still Interested in ImmunoCellular Therapeutics?
Investing in delisted pink sheets can be risky, as the pink sheet is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |